Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 14 EP applications Elizabeth Anne Drury has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after August 22, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12789372

NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

IPC classification:
A61K 31/17, C07D 241/20, C07D 239/42, C07D 237/20, C07D 217/24, C07D 213/75, C07C 275/42, A61P 31/00, A61P 17/00, A61P 3/00
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12799114

METHODS OF TREATMENT AND PREVENTION OF EYE DISEASES

IPC classification:
A61K 31/5375, A61K 31/395, A61P 27/02
Applicant:
Glaxo Group Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP12789931

NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

IPC classification:
A61K 31/553, C07D 498/04, A61P 3/00
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13856479

NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

IPC classification:
A61K 31/553
Applicant:
GlaxoSmithKline LLC
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14723475

IMPROVED POXVIRAL VACCINES

IPC classification:
C07K 14/705, A61K 39/00
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
EXAMINATION IN PROGRESS
EP14713598

PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS

IPC classification:
A61P 1/06, A61K 31/4412, C07D 213/69, C07D 413/12, C07D 401/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
PATENT GRANTED
EP15193141

NOVEL METHOD AND COMPOSITIONS

IPC classification:
A61K 39/35, C07K 14/35, C07K 14/005, A61K 39/21, A61K 39/12, A61K 39/015, A61K 39/00, C12N 15/861, C07K 14/445, C07K 14/16
Applicant:
GlaxoSmithKline Biologicals SA
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP15766655

CRYSTALLINE FORMS OF 2-(4-(4-ETHOXY-6-OXO-1,6-DIHYDROPYRIDIN-3-YL)-2-FLUOROPHENYL)-N-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)ACETAMIDE

IPC classification:
A61P 35/00, A61K 31/4427, C07D 413/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
Request for examination was made
EP15840612

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

IPC classification:
A61P 43/00, A61P 1/00, A61P 35/00, A61K 31/4427, A61K 31/4412, C07D 239/22, C07D 217/24, C07D 211/94
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
Request for examination was made
EP15767599

PYRIDONE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS

IPC classification:
A61P 35/00, A61K 31/4412, C07D 213/69
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
Request for examination was made
EP15801271

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

IPC classification:
A61P 25/28, A61P 9/00, A61P 3/10, A61K 31/551, C07D 471/18
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
Request for examination was made
EP15801270

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

IPC classification:
A61P 25/28, A61P 9/00, A61P 3/10, A61K 31/551, C07D 471/18
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
Request for examination was made
EP15816522

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

IPC classification:
A61P 25/28, A61P 9/00, A61P 3/10, A61K 31/4995, C07D 487/18
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
Request for examination was made
EP15804601

SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS

IPC classification:
C07D 487/18, A61P 25/28, A61P 9/00, A61P 3/10, A61K 31/551
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Elizabeth Anne Drury, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature